

# Ezra E Cohen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7120080/publications.pdf>

Version: 2024-02-01

128  
papers

12,311  
citations

38742  
50  
h-index

27406  
106  
g-index

133  
all docs

133  
docs citations

133  
times ranked

14591  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 393, 156-167.	13.7	1,153
2	PI3KÎ³ is a molecular switch that controls immune suppression. <i>Nature</i> , 2016, 539, 437-442.	27.8	884
3	Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4708-4713.	1.6	593
4	Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2003, 21, 1980-1987.	1.6	568
5	Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 632-641.	7.0	525
6	Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2735-2743.	1.6	458
7	American Cancer Society Head and Neck Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 203-239.	329.8	419
8	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
9	Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2009, 27, 1864-1871.	1.6	353
10	Stereotactic body radiotherapy for multisite extracranial oligometastases. <i>Cancer</i> , 2012, 118, 2962-2970.	4.1	295
11	Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 450-462.	10.7	287
12	Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3305-3313.	1.6	269
13	Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. <i>Lancet Oncology</i> , The, 2009, 10, 247-257.	10.7	263
14	Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non-Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. <i>Journal of Clinical Oncology</i> , 2007, 25, 3978-3984.	1.6	240
15	The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2009, 69, 3021-3031.	0.9	236
16	Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2005, 11, 8418-8424.	7.0	224
17	The Expanding Role of Systemic Therapy in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1743-1752.	1.6	199
18	Current Treatment Options for Metastatic Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 35-46.	3.0	197

#	ARTICLE	IF	CITATIONS
19	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. <i>Radiotherapy and Oncology</i> , 2021, 156, 281-293.	0.6	157
20	Role of Epidermal Growth Factor Receptor Pathway—Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2006, 24, 2659-2665.	1.6	144
21	Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. <i>Clinical Cancer Research</i> , 2012, 18, 2056-2065.	7.0	141
22	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	1.6	141
23	Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2015, 51, 291-298.	1.5	136
24	An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4546-4552.	1.6	135
25	Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. <i>Nature Genetics</i> , 2014, 46, 939-943.	21.4	126
26	Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR. <i>Clinical Cancer Research</i> , 2005, 11, 8105-8108.	7.0	125
27	B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 3345-3359.	7.0	117
28	Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 883-892.	10.7	116
29	The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification. <i>Clinical Cancer Research</i> , 2021, 27, 689-703.	7.0	113
30	Erlotinib and the Risk of Oral Cancer. <i>JAMA Oncology</i> , 2016, 2, 209.	7.1	111
31	A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 766-770.	3.4	106
32	Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. <i>Cancer</i> , 2014, 120, 2694-2703.	4.1	106
33	A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2012, 18, 2336-2343.	7.0	104
34	New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors. <i>Clinical Cancer Research</i> , 2010, 16, 2489-2495.	7.0	102
35	A Feed-Forward Loop Involving Protein Kinase C $\delta$ and MicroRNAs Regulates Tumor Cell Cycle. <i>Cancer Research</i> , 2009, 69, 65-74.	0.9	99
36	Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. <i>Nature Communications</i> , 2019, 10, 5546.	12.8	98

#	ARTICLE	IF	CITATIONS
37	Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2427-2437.	1.6	88
38	Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. <i>Clinical Cancer Research</i> , 2019, 25, 4211-4223.	7.0	85
39	Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3336-3343.	1.6	75
40	Single Sample Expression-Anchored Mechanisms Predict Survival in Head and Neck Cancer. <i>PLoS Computational Biology</i> , 2012, 8, e1002350.	3.2	75
41	An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1227-1239.	2.3	73
42	Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2017, 7, 246-253.	2.1	73
43	A Genome-Wide Screen for Microdeletions Reveals Disruption of Polarity Complex Genes in Diverse Human Cancers. <i>Cancer Research</i> , 2010, 70, 2158-2164.	0.9	72
44	Protein Kinase C $\eta$ Mediates Epidermal Growth Factor–Induced Growth of Head and Neck Tumor Cells by Regulating Mitogen-Activated Protein Kinase. <i>Cancer Research</i> , 2006, 66, 6296-6303.	0.9	70
45	Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. <i>Annals of Oncology</i> , 2017, 28, 2526-2532.	1.2	70
46	Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. <i>Cancer</i> , 2011, 117, 4671-4678.	4.1	68
47	Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. <i>Modern Pathology</i> , 2021, 34, 532-541.	5.5	63
48	Planned Post-Chemoradiation Neck Dissection: Significance of Radiation Dose. <i>Laryngoscope</i> , 2006, 116, 33-36.	2.0	61
49	Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 358-365.	2.5	61
50	Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients. <i>Clinical Cancer Research</i> , 2012, 18, 4785-4793.	7.0	61
51	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , 2020, 26, 5153-5161.	7.0	58
52	Characteristics Associated With Swallowing Changes After Concurrent Chemotherapy and Radiotherapy in Patients With Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2008, 134, 1060.	1.2	53
53	Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. <i>Head and Neck</i> , 2009, 31, 1013-1021.	2.0	53
54	Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. <i>Nature Communications</i> , 2016, 7, 13019.	12.8	51

#	ARTICLE	IF	CITATIONS
55	Epidermal growth factor receptor directed therapy in head and neck cancer. Critical Reviews in Oncology/Hematology, 2006, 57, 25-43.	4.4	46
56	A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemotherapy and Pharmacology, 2014, 74, 1261-1270.	2.3	44
57	Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer. Journal of the National Cancer Institute, 2018, 110, 1393-1399.	6.3	43
58	Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Translational Research, 2011, 157, 265-272.	5.0	42
59	Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncology, 2012, 48, 887-892.	1.5	42
60	Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncology, 2018, 80, 16-22.	1.5	42
61	A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. , 2019, 7, 342.		40
62	Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. Clinical Cancer Research, 2021, 27, 6075-6082.	7.0	40
63	Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nature Communications, 2021, 12, 2383.	12.8	39
64	Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 678-684.	0.8	38
65	Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Molecular Oncology, 2013, 7, 359-368.	4.6	37
66	HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. Cancer Research, 2020, 80, 732-746.	0.9	36
67	Multidisciplinary Care of Laryngeal Cancer. Journal of Oncology Practice, 2016, 12, 717-724.	2.5	35
68	Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer, 2020, 126, 3972-3981.	4.1	34
69	Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. Journal of Geriatric Oncology, 2013, 4, 327-333.	1.0	33
70	Race and competing mortality in advanced head and neck cancer. Oral Oncology, 2014, 50, 40-44.	1.5	27
71	Chemoradiation for patients with large-volume laryngeal cancers. Head and Neck, 2012, 34, 1162-1167.	2.0	26
72	p62/SQSTM1 Accumulation in Squamous Cell Carcinoma of Head and Neck Predicts Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitors. PLoS ONE, 2014, 9, e90171.	2.5	26

#	ARTICLE	IF	CITATIONS
73	Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 53-58.	1.5	26
74	Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. <i>Journal of the National Cancer Institute</i> , 2021, 113, 171-181.	6.3	25
75	A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. <i>Quality of Life Research</i> , 2007, 16, 1615-1626.	3.1	24
76	Multidisciplinary Care of the Patient with Head and Neck Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 179-215.	1.5	23
77	Efficient Cisplatin Prodrug Delivery Visualized with Sub-100 nm Resolution: Interfacing Engineered Thermosensitive Magnetomicelles with a Living System. <i>Advanced Materials Interfaces</i> , 2014, 1, 1400182.	3.7	22
78	Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. <i>Targeted Oncology</i> , 2015, 10, 501-508.	3.6	22
79	Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 5420-5426.	7.0	22
80	The Rise of HPV-Positive Oropharyngeal Cancers in the United States. <i>Cancer Prevention Research</i> , 2015, 8, 9-11.	1.5	21
81	Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 157-167.	4.1	21
82	Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. <i>Journal of Cancer Education</i> , 2018, 33, 622-626.	1.3	20
83	Novel therapeutic targets in squamous cell carcinoma of the head and neck. <i>Seminars in Oncology</i> , 2004, 31, 755-768.	2.2	19
84	Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors. <i>Current Cancer Drug Targets</i> , 2007, 7, 666-673.	1.6	19
85	Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). <i>Oral Oncology</i> , 2015, 51, 399-408.	1.5	19
86	High Survival and Organ Function Rates After Primary Chemoradiotherapy for Intermediate-Stage Squamous Cell Carcinoma of the Head and Neck Treated in a Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 3438-3444.	1.6	18
87	Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. <i>Frontiers in Oncology</i> , 2018, 8, 435.	2.8	18
88	Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. <i>Ecological Management and Restoration</i> , 2008, 21, 514-521.	0.4	17
89	Factors Associated With Long-term Speech and Swallowing Outcomes After Chemoradiotherapy for Locoregionally Advanced Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2010, 136, 1226.	1.2	17
90	Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens. <i>Cancer Immunology Research</i> , 2019, 7, 40-49.	3.4	17

#	ARTICLE	IF	CITATIONS
91	A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. PLoS ONE, 2016, 11, e0152995.	2.5	17
92	Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers. Cancers, 2022, 14, 33.	3.7	17
93	Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy. Oral Oncology, 2013, 49, 1025-1031.	1.5	16
94	Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. Journal of Medical Economics, 2020, 23, 442-447.	2.1	16
95	Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients. Translational Cancer Research, 2020, 9, 203-209.	1.0	15
96	Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. Biomaterials, 2020, 248, 120032.	11.4	14
97	DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. PLoS ONE, 2014, 9, e102112.	2.5	14
98	Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncology, 2012, 48, 1025-1030.	1.5	13
99	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 309-317.	2.3	12
100	Novel targeted therapies in head and neck cancer. Expert Opinion on Investigational Drugs, 2012, 21, 281-295.	4.1	11
101	A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer. Cancer Investigation, 2007, 25, 435-444.	1.3	10
102	Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non-Small-Cell Lung Cancer, A Phase II Trial. Clinical Lung Cancer, 2012, 13, 123-128.	2.6	10
103	Selection of Head and Neck Cancer Patients for Intensive Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 157-166.	0.8	10
104	Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. Cancer Letters, 2015, 359, 269-274.	7.2	9
105	Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. Frontiers in Oncology, 2021, 11, 738626.	2.8	9
106	Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244. Journal of the American Academy of Dermatology, 2011, 64, e17-e19.	1.2	8
107	Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Hematology/Oncology Clinics of North America, 2004, 18, 81-90.	2.2	6
108	Analysis of CDK12 alterations in a pan-cancer database. Cancer Medicine, 2022, 11, 753-763.	2.8	6



#	ARTICLE	IF	CITATIONS
109	SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Journal of Translational Medicine, 2019, 17, 429.	4.4	5
110	Treatment of metastatic urothelial cancer in the post-MVAC era. World Journal of Urology, 2001, 19, 126-132.	2.2	3
111	Open Access in biomedical sciences: What the current turning point means more specifically to Oral Oncology contributors and readers. Oral Oncology, 2013, 49, 985-986.	1.5	3
112	Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clinical Cancer Research, 2015, 21, 5092-5099.	7.0	3
113	Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report. Journal of Otolaryngology - Head and Neck Surgery, 2022, 51, 5.	1.9	3
114	Serum antibodies open the door to prediction and prognostication in human papillomavirus-related head and neck cancer. Cancer, 2017, 123, 4310-4313.	4.1	1
115	Did Everolimus Break the Rules?. Clinical Cancer Research, 2021, 27, 3807-3808.	7.0	1
116	Locally advanced non-small cell lung cancer. Current Treatment Options in Oncology, 2001, 2, 27-42.	3.0	0
117	A Disturbance in the Force—Mitochondrial Mutations in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2007, 13, 4317-4319.	7.0	0
118	Personalizing cancer care: updates on head and neck cancer. Expert Review of Anticancer Therapy, 2009, 9, 1219-1222.	2.4	0
119	The Next Phase of Chemoprevention Research. Cancer Prevention Research, 2011, 4, 293-295.	1.5	0
120	Magnetomicelles: Efficient Cisplatin Prodrug Delivery Visualized with Sub-100 nm Resolution: Interfacing Engineered Thermosensitive Magnetomicelles With a Living System (Adv. Mater. Interfaces) Tj ETQq0 0.07gBT / Overlock 10	1.5	0
121	The ACR appropriateness criteria® for thyroid carcinoma: Searching for consensus in a rapidly evolving area. Oral Oncology, 2014, 50, 575-576.	1.5	0
122	Reply to S. Chakraborty et al. Journal of Clinical Oncology, 2015, 33, 968-968.	1.6	0
123	Considering the survivorship care needs of head and neck cancer survivors. Oral Oncology, 2016, 57, 61-62.	1.5	0
124	Postoperative Management of High-Risk Resectable Head and Neck Cancer. , 2016, , 607-615.		0
125	Characterizing an Ultra-High-Risk Subset of Patients With Hypopharynx and Larynx Cancer. JAMA Oncology, 2018, 4, 989.	7.1	0
126	p16 status and choice of chemotherapy in the KEYNOTE-040 study — Authors' reply. Lancet, The, 2019, 394, 1323.	13.7	0



#	ARTICLE	IF	CITATIONS
127	Targeted Therapies in Head and Neck Cancer. , 2005, , 239-261.		0
128	Inevitable Progress-Relying on the Immune System, Not Chance. Clinical Cancer Research, 2021, , clincanres.3739.2021.	7.0	0